Maria Fermer-Lagerstrom
AstraZeneca R&D
Goeteborg, O, Sweden
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF.
Journal: JACC. Heart failure
Published: October 06, 2022
Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction.
Journal: European journal of heart failure
Published: July 17, 2021
Generalizability of HFA-PEFF and H2FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF.
Journal: Journal of cardiac failure
Published: October 29, 2020
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
Journal: Clinical and translational science
Published: April 09, 2020
Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction.
Journal: Contemporary clinical trials communications
Published: April 06, 2020
Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial.
Journal: Molecular therapy. Methods & clinical development
Published: February 27, 2020
Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability.
Journal: Clinical pharmacology in drug development
Published: May 10, 2019
PROspective evaluation of coronary FLOW reserve and molecular biomarkers in patients with established coronary artery disease the PROFLOW-trial: cross-sectional evaluation of coronary flow reserve.
Journal: Vascular health and risk management
Published: March 17, 2019
Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes.
Journal: Nature communications
Published: October 23, 2018
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers.
Journal: British journal of clinical pharmacology
Published: June 18, 2018
Last Updated: 09/26/2026